Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04275661 | Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery | completed | Phase 2 | 60 | Assiut UniversityOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03781063 | Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | completed | Phase 2 | 100 | Sermonix Pharmaceuticals Inc.INDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT01494662 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | completed | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02086578 | Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions | completed | Phase 2 | 100 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02668666 | Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 49 | Oana Danciu, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05280067 | ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES(ZGMBC) | completed | Phase 2 | 10 | Zetagen Therapeutics, IncINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05963984 | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants(SUMIT-BC) | completed | Phase 2 | 60 | Carrick Therapeutics LimitedINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT06570811 | Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients | completed | Phase 2 | 40 | Damanhour UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03095352 | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | completed | Phase 2 | 76 | Laura Huppert, MD, BAOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02760030 | Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 14 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT02783690 | A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation | completed | Phase 2 | 88 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05520723 | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED(PRIMED) | completed | Phase 2 | 50 | MedSIROTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05190770 | A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT01975142 | Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. | completed | Phase 2 | 155 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03280563 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer(MORPHEUS HR+BC) | completed | Phase 1 / Phase 2 | 144 | Hoffmann-La RocheINDUSTRY | 3 | Nov 10, 2025 | clinicaltrials |
| NCT02593175 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03822468 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer(AMALEE) | completed | Phase 2 | 376 | Novartis PharmaceuticalsINDUSTRY | 23 | Oct 16, 2025 | clinicaltrials |
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | completed | Phase 2 | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04892342 | Study of ESG401 in Adults With Solid Tumors | completed | Phase 1 / Phase 2 | 156 | Shanghai Escugen Biotechnology Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT02958852 | A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer(ABC-SE) | completed | Phase 2 | 126 | Lund University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT02007512 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 2 | 247 | PfizerINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT03093350 | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer(TACTIC) | completed | Phase 2 | 12 | Baylor College of MedicineOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05549505 | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | completed | Phase 2 | 152 | Arvinas Inc.INDUSTRY | 4 | Aug 29, 2025 | clinicaltrials |
| NCT07143097 | Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer | completed | Phase 2 | 80 | Beni-Suef UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | completed | Phase 2 / Phase 3 | 130 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01149083 | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT04300790 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients(METALLICA) | completed | Phase 2 | 69 | MedSIROTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05417451 | Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors | completed | Phase 2 | 46 | University of Illinois at ChicagoOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07081581 | Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery | completed | Phase 2 | 75 | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03755141 | Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer | completed | Phase 2 | 109 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05632848 | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT04352777 | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | completed | Phase 2 | 18 | Duke UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06355024 | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | completed | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04290897 | Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors | completed | Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03094052 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | completed | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04420598 | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease(DEBBRAH) | completed | Phase 2 | 41 | MedSIROTHER | 2 | Jun 24, 2025 | clinicaltrials |
| NCT04132960 | Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis(DAISY) | completed | Phase 2 | 186 | UNICANCEROTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02061085 | Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment(MERIBEL) | completed | Phase 2 | 53 | MedSIROTHER | 1 | Jun 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2026source: clinicaltrials